NEWS

Experience with Surpass Evolve

LINNC Americas - What was DAY 2 about?

LINNC Americas - Daily report Day 1

LINNC Americas 2023 streaming in progress

Scientia Vascular Receives FDA Clearance for Aristotle Colossus, the Onl...

SALT LAKE CITY, UTAH – March 9, 2023  Scientia Vascular, a leader and pioneer in differentiated neurovascular access technology, announces FDA 510k clearance of the Aristotle Colossus macrowire. Like its predecessors the Aristotle 18 and Aristotle 24 that have expanded treatment options in thousands of procedures to date, Aristotle Colossus utilizes breakthrough microfabrication design technology. This advancement in manufacturing allows for a soft, atraumatic tip and is designed to support the tracking of large bore catheters to the treatment site and drive superior navigability of distal, tortuous anatomy. The combination of these benefits for patients and clinicians will impact a myriad of procedures in both ischemic and hemorrhagic stroke care. 

Discover the selection of e-posters of LINNC Americas

International Women's Day special report

Podcast Ep #7 featuring Prof. Vitor Mendes Pereira

VESALIO Announces Initial Use of its Uniquely Designed and FDA-approved...

Nashville, Tennessee - (FEB 23, 2023) – VESALIO announces the successful initial use of its NeVa VS device in the United States for the treatment of post-aneurysmal subarachnoid hemorrhage (aSAH) cerebral vasospasm. Vasospasm is the most common complication of aSAH and is the main cause of delayed morbidity and mortality. NeVa VS is the only FDA-approved device for this indication and the only device on the market specifically designed to treat life-threatening vasospasm.

Phenox Inc. announces the presentation of the PROST Clinical Trial at th...

[Irvine, CA] - phenox Inc. a leading medical device company in the Neurovascular industry, announced the presentation of the primary results of The pRESET for Occlusive Stroke Treatment (PROST) Randomized Clinical Trial at the International Stroke Conference in Dallas, TX on February 8th at 9:30am CST. This highly anticipated event marks a significant milestone in the company's efforts to advance the treatment of occlusive stroke.